Feladilimab

菲阿迪利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameFeladilimab
Drug Alias NameGSK-3359609GSK-609
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInducible T-cell costimulator agonists
TargetsInducible T-cell costimulator
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsMultiple Myeloma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[28] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesGlaxosmithkline (Ireland) LtdGlaxo Operations Uk LtdGlaxosmithkline (China) Investment Co Ltd
Active IndicationsMultiple Myeloma
Inactive IndicationsSolid tumoursHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 

Other Information

ATC CodeN/A
Related LinksN/A